Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Impact Of Adjuvant Interferon Therapy On Survival Outcomes For Cutaneous Melanoma With Parotid Involvement.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Impact Of Adjuvant Interferon Therapy On Survival Outcomes For Cutaneous Melanoma With Parotid Involvement.

Related Experiment Video

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

Impact of Adjuvant Interferon Therapy on Survival Outcomes for Cutaneous Melanoma With Parotid Involvement.

Erin Kim1, Sarah A Raven2, Nicholas R Lenze3

  • 1University of Michigan Medical School, Ann Arbor, Michigan, U.S.A.

The Laryngoscope
|October 17, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Adjuvant interferon therapy may improve survival for head and neck cutaneous melanoma (HNCM) involving the parotid gland. This immunotherapy shows potential benefits for overall survival in stage III HNCM patients.

Keywords:
head and neck neoplasmsimmunotherapyinterferonmelanoma

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K

Related Experiment Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K

Area of Science:

  • Oncology
  • Dermatology
  • Surgical Oncology

Background:

  • Cutaneous melanoma of the head and neck (HNCM) involving the parotid gland presents unique treatment challenges.
  • Adjuvant therapies are crucial for managing high-risk HNCM, particularly stage III disease.
  • The role of immunotherapy, such as interferon, in this specific HNCM subset requires further elucidation.

Purpose of the Study:

  • To compare the 5-year overall survival (OS) and recurrence-free survival (RFS) rates.
  • To evaluate the efficacy of adjuvant interferon therapy versus other adjuvant treatments or no adjuvant therapy.
  • To assess outcomes for patients with stage III HNCM involving the parotid gland.

Main Methods:

  • Retrospective cohort study of 82 patients undergoing parotidectomy for HNCM with parotid involvement (2000-2014).
parotid
  • Analysis included patients receiving adjuvant interferon, adjuvant radiation therapy (RT), or no adjuvant therapy.
  • Time-to-event analyses utilized Kaplan-Meier curves and Cox proportional hazards models.

    • Main Results:

    • Adjuvant interferon therapy was associated with a crude 5-year OS rate of 95.0%.
    • In adjusted analyses, adjuvant interferon significantly improved 5-year OS compared to adjuvant RT (HR 0.10, p=0.034).
    • No significant association was found between adjuvant interferon and 5-year RFS in the adjusted model.

    Conclusions:

    • Adjuvant interferon therapy may enhance survival outcomes in surgically treated stage III HNCM with parotid gland involvement.
    • Findings support the use of immunotherapy in melanoma, especially when involving the lymphatic-rich parotid gland.
    • Further research is warranted to confirm the specific role and optimal use of interferon in this patient population.